Working… Menu

A Study of Anti-PD-1 AK105 in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03722147
Recruitment Status : Unknown
Verified October 2018 by Akeso.
Recruitment status was:  Recruiting
First Posted : October 26, 2018
Last Update Posted : October 30, 2018
Information provided by (Responsible Party):

Brief Summary:
This is a single-arm, open-label, multicenter, phase I/II study to evaluate efficacy and safety of AK105 in patients with relapsed or refractory classic Hodgkin lymphoma.

Condition or disease Intervention/treatment Phase
Hodgkin's Lymphoma Biological: AK105 Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single-arm, Multicenter, Open-label, Phase I/II Study of AK105 as Monotherapy in Relapsed or Refractory Classic Hodgkin Lymphoma
Actual Study Start Date : August 13, 2018
Estimated Primary Completion Date : March 1, 2020
Estimated Study Completion Date : September 1, 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: AK105
AK105 200 mg intravenously (IV) every-2-weeks (Q2W)
Biological: AK105
AK105 200 mg intravenously (IV) every-2-weeks (Q2W)

Primary Outcome Measures :
  1. Objective response rate (ORR) assessed by Independent Radiology Review Committee (IRRC) per the Lugano 2014 Classification [ Time Frame: Up to 2 years ]
    ORR defined as the proportion of subjects who achieves a best overall response of CR or PR, assessed by IRRC per the Lugano 2014 Classification.

  2. Number of subjects with adverse events (AEs) [ Time Frame: From the time of informed consent signed through 90 days after the last dose of AK105 ]
    An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment.

Secondary Outcome Measures :
  1. ORR assessed by Investigator [ Time Frame: Up to 2 years ]
    ORR defined as the proportion of subjects who achieves a best overall response of CR or PR, assessed by Investigator per the Lugano 2014 Classification.

  2. Duration of Response (DoR) [ Time Frame: Up to 2 years ]
    From the date that CR or PR are first occurred to the date of objective disease progression or death, whichever occurs first.

  3. Progression-free Survival (PFS) [ Time Frame: Up to 2 years ]
    From the first dose of AK105 to the date of the date of objective disease progression or death, whichever occurs first.

  4. Disease control rate (DCR) [ Time Frame: Up to 2 years ]
    DCR defined as the proportion of subjects response of CR, PR, or SD (subjects achieving SD will be included in the DCR if they maintain SD for ≥8 weeks) per the Lugano 2014 Classification.

  5. Minimum observed concentration (Cmin) of AK105 at steady state [ Time Frame: From first dose of AK105 through 30 days after last dose of AK105 ]
    The endpoints for assessment of PK of AK105 include serum concentrations of AK105 at different timepoints after AK105 administration.

  6. Number of subjects who develop detectable anti-drug antibodies (ADAs) [ Time Frame: From first dose of AK105 through to 90 days after last dose of AK105 ]
    The immunogenicity of AK105 will be assessed by summarizing the number of subjects who develop detectable antidrug antibodies (ADAs).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Written and signed informed consent
  2. Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1
  3. Histologically confirmed classic Hodgkin's lymphoma (cHL) (based on tumor tissue obtained within 3 years prior to enrollment).
  4. Relapsed (disease progression during or after most recent therapy) or refractory (failure to achieve CR or PR after most recent therapy) cHL and meet any of the following criterions:

    1. Recurrence or disease progression after autologous hematopoietic stem cell transplantation.
    2. For subject without receiving , the subject has received at least 2 lines of prior systemic chemotherapy. Refractory subject is defined as subject who has not achieved PR after at least 2 cycles of treatment, or subject who has not achieved CR after at least 4 cycles of treatment. If the best response to treatment is PD or the reason for ending the treatment is PD, the subject is consider as refractory without requirement on the number of cycles of treatment that the subject has received. For relapsed subjects, disease progression occurred for the subject who has received at least 2 line of prior systemic chemotherapy.
  5. Subject must have at least one measurable lesion (> 1.5 cm in the longest diameter, or > 1 cm in the longest diameter with uptake on 18FDG-PET)according to the Lugano 2014 criteria.
  6. Adequate organ functions.
  7. Use effective methods of contraception.

Exclusion Criteria:

  1. Known nodular lymphoma predominant Hodgkin lymphoma or Grey zone lymphoma.
  2. Lymphoma involving the central nervous system.
  3. Participated in other clinical studies of experimental drugs or received research treatment or used experimental equipment within 4 weeks prior to the first dose of AK105.
  4. Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or the follow-up period of an interventional study.
  5. Receipt of the last radiotherapy or the last dose of anticancer therapy (chemotherapy, target therapy, immunotherapy or tumor embolism, etc.) with 4 weeks prior to the first dose of AK105. Receipt of the last dose of nitrocarbamide or mitomycin C within 6 weeks prior to the first dose of AK105.
  6. Prior exposure to any anti-PD-1, anti-PD-L1, anti-CTL4 antibody or any other antibody or drug targeting T-cell costimulation or checkpoint pathways such as ICOS, or agonists such as CD40, CD137, GITR, OX40 etc..
  7. Had other active malignancies within 5 years prior to enrollment. Locally curable cancer (manifested as cured) is excluded, such as basal or cutaneous squamous cell carcinoma, superficial bladder cancer, cervical or breast carcinoma in situ.
  8. Active, known or suspected autoimmune diseases, or a history of the disease within the past 2 years, except the following: vitiligo, alopecia, Graves' disease, psoriasis or eczema that do not require systemic treatment within the last 2 years, hypothyroidism (caused by autoimmune thyroiditis) only requiring a stable dose of hormone replacement therapy, type I diabetes requiring only a stable dose of insulin replacement therapy, or diseases not expected to recur in the absence of external triggering factors.
  9. Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis or chronic diarrhea).
  10. Subjects with a condition requiring systemic treatment with either corticosteroid (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration.
  11. History of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).
  12. History of primary immunodeficiency.
  13. History of active tuberculosis.
  14. History of allogeneic stem cell transplantation or organ transplantation.
  15. Autologous hematopoietic stem cell transplantation performed within 90 days prior to the first dose of AK105.
  16. History of gastrointestinal perforation and /or within 6 months prior to enrollment.
  17. History of interstitial lung disease.
  18. Patients with untreated chronic hepatitis B or with HBV DNA exceeding 500 IU/mL, or with active hepatitis C should be excluded. Inactive HBsAg carriers, treated and stable hepatitis B patients (HBV DNA < 500 IU/mL), or cured hepatitis C patients can be enrolled. For patients with positive HCV antibody, they are eligible to participate in the study only if the test result of HCV RNA is negative.
  19. Major surgical procedure (as defined by the investigator) within 30 days prior to the first dose of AK105 or still recovering from prior surgery. Local procedures (eg, placement of a systemic port, core needle biopsy, and prostate biopsy) are allowed if completed at least 24 hours prior to the administration of the first dose of study treatment.
  20. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage.
  21. Active infections requiring systemic treatment.
  22. Uncontrolled concurrent disease, including but not limited to, persistent or active infection, symptomatic congestive heart failure (according to the New York heart association functional class defined 3 or 4), out of control of high blood pressure, unstable angina, arrhythmia, severe peptic ulcer or gastritis, activity, or mental illness/social status which will limit the participants compliance requirements or damage to the participants to provide written informed consent.
  23. Unresolved toxicities from prior anticancer therapy, defined as having not resolved to National Cancer Institute's (NCI's) Common Terminology Criteria for Adverse Events (CTCAE) (NCI CTCAE v4.03) Grade 0 or 1, or to levels dictated in the inclusion/exclusion criteria with the exception of alopecia. Subjects with irreversible toxicity that is not reasonably expected to be exacerbated by the study drug may be included (eg, hearing loss) after consultation with the medical monitor. Subjects with ≤ Grade 2 neuropathy will be evaluated on a case-by-case basis after consultation with the medical monitor.
  24. Receipt of live or attenuated vaccination within 30 days prior to the first dose of AK105, or plan to have live or attenuated vaccination during the study.
  25. Known allergy or reaction to any component of the AK105 formulation.
  26. History of severe allergic reaction to any other monoclonal antibodies.
  27. Women who are pregnant or nursing.
  28. Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03722147

Layout table for location contacts
Contact: Xiaoping Jin +86 (0760) 8987 3999

Layout table for location information
China, Beiing
Beijing Cancer Hospital Recruiting
Beijing, Beiing, China, 100142
Contact: Ling Zhang    13810378747   
Principal Investigator: Jun Zhu, MD         
Principal Investigator: Yuqin Song, MD         
Sponsors and Collaborators
Layout table for additonal information
Responsible Party: Akeso Identifier: NCT03722147    
Other Study ID Numbers: AK105-201
First Posted: October 26, 2018    Key Record Dates
Last Update Posted: October 30, 2018
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Akeso:
Classic Hodgkin Lymphoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Hodgkin Disease
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases